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CONSUMPTION OF FIXED-DOSES IN THE ARTERIAL HYPERTENSION 
TREATMENT
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OBJECTIVES: To determine the incidence of cardiovascular events (CVE) and the 
sanitary costs in function of the compliance, persistence and blood pressure control; 
comparing patients consuming ﬁ xed-doses (FD) in front of free-doses (FD) in the 
treatment of HTA. METHODS: Observational-multicentric design. It was included 
patients >30 years appertaining to six team of primary care and two hospitals, that 
started pharmacological treatment for hypertension during 2006. It was established 
two study groups: FD (IECA/diuretics; ARA II/diuretics) and FD (IECA + DIU; ARA 
II + DIU, separately). Main measures: socio-demographics, co-morbidity, parameters, 
Charlson-index, compliance, persistence and control therapeutical objects (criteria: 
ESH-ESC). It was determined the accumulated incidence tax of CVE and a total-cost 
model (differentiating: sanitary/direct; non-sanitary/indirect). The patients’ pursuit 
was realized during two years. Statistic analysis: logistic regression, proportional risk 
model of Cox and the ANCOVA, P < 0.05. RESULTS: It was recruited 1605 patients, 
1.112 (69.3%) in FD and 493 (30.7%) in FD, P < 0.001; age average: 69.4 (12.2) 
years; women: 55.5%. Patients in FD were associated with the isquemic cardiopathy 
OR = 1.4 (CI of 95%: 1.1–2.0) and organic insufﬁ ciencies OR = 1.5 (IC of 95%: 
1.2–2.1), P < 0.031. Patients in FD showed a better therapeutic compliance (77.6 vs. 
71.9; P < 0.001) and treatment persistence at 24 months (62.1% [CI of 95%: 56.3–
67.9%] vs. 49.7% [CI of 95%: 38.5–60.9%]; P < 0.001. The optimum control of the 
arterial pressure in FD was higher (48.9% [CI of 95%: 43.0–54.8%] vs. 46.7% [CI 
of 95%: 35.6–57.8%]; P < 0.001). The accumulated incidence tax of vasculocerebral 
accident in FD was 4.6% vs. 2.4%; p = 0.041. The total cost in FD was lower (c1650.7 
vs. c1674.8; P < 0.001), in specialized care (c316.1 vs. c382.9; P < 0.001) and loses 
of labour productivity (c44.5 vs. c88.4; P < 0.001). CONCLUSIONS: Treatment of 
compliance and persistence for hypertension in FD improve the therapeutical control, 
causing a reduction of CVE and total sanitary costs.
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ANTIARRYTHMIC DRUGS IN THE CLINCAL PRACTICE IN SPAIN
Pastor Fuentes A1, Moreno Reviriego S2, Garcia Coscolin T3, Pérez Alcántara F4
1Universitary Hospital, Getafe, Madrid, Getafe, Madrid, Spain; 2Universitary Hospital La Paz, 
Madrid, Madrid, Spain; 3Sanoﬁ -Aventis, Madrid, Madrid, Spain; 4Oblikue Consulting, 
Barcelona, Spain
OBJECTIVES: Antiarrhythmic drugs (AADs) are considered the ﬁ rst-line treatment of 
atrial ﬁ brillation (AF). However, they present a high adverse effects (AEs) rate. The 
aim of the present study is to know the health resources and the costs associated with 
the management of AEs of main AADs. METHODS: The incidence of AE’s of main 
AADs (amiodarone, sotalol, ﬂ ecainide and propafenone) has been obtained from the 
Summary of product characteristics or correspondent clinical trials. The use of health 
resources associated with the management of the AEs has been evaluated by a panel 
of cardiology experts. Finally, all these clinical data regarding AE’s incidence derived, 
has been combined with economic data from the Spanish literature and e- salud 
data,an Spanish database about health care costs. The study has been carried using 
National Health System perspective. RESULTS: The most expensive AEs have been 
pulmonary ﬁ brosis: c2,177.49, cardiac events (mainly tachycardia or bradycardia): 
c1,422.08, and endocrine disorders (as hyperthyroidism: c244.06c and hypothy-
roidsm: c239.06 c). When costs are analyzed in relation with the drug to which are 
associated, results are as follow: sotalol has been associated with the highest costs: 
c269.42, followed by ﬂ ecainide: 132.25 c, and amiodarone: 127,82, whereas propafe-
none has been associated to the lowest cost: c48.09. However, although amiodarone 
is not the AAD associated with the highest cost, considering current Spanish AADs 
market, it is the one that has more economic repercussion. CONCLUSIONS: Current 
AADs may cause AEs and their management is related to health resources consump-
tion. Pulmonary and cardiac events have been associated to the major cost. Consider-
ing current clinical practice in Spain, amiodarone is the treatment that supposes a 
major budget impact for the National Health Service.
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OBJECTIVES: To assess the cost of the basic course of pharmacotherapy of arterial 
hypertension (AH) of inhibitors-ACE, direct costs associated with the correction of 
side effects (SE), developing on the background of their application with further 
pharmacoeconomics evaluation of inhibitors-ACE. METHODS: Cost analysis, model-
ing. a consideration of the basic price of therapy trade names (TN) inhibitors-ACE 
INN: enalapril, lisinopril and the calculation of direct costs associated with correction 
of SE in patients diagnosed with stage II AH. Medical patients’ route, the cost structure 
were modeled by questioning physicians, cardiologists of Institute of Gerontology, 
Clinical Hospital ¹ 55, Moscow. The study takes into account the cost: symptomatic 
therapy, specialist consultations, emergency care, hospital bed-days, laboratory and 
instrumental manipulations. Data registered in RF TN obtained from the site www.
regmed.ru, information about prices—www.medlux.ru, www.cardioweb.ru. We took 
into account recommendations of standards of care for patients with AH, developed 
by Health Ministry of Russia. The cost of the basic course of pharmacotherapy and 
PE are estimated at 30-day time period for 1 patient. Average daily dose the drugs 
accounted for enalapril—5 mg/day, lisinopril—10 mg/day. RESULTS: The develop-
ment of side effects (cough, arterial hypotension, allergies, headache, etc.) was the 
cause of drug withdrawal enalapril in 5.3% of patients, lisinopril at 3.8% of patients. 
The study calculated the cost of courses were the main pharmacotherapy TN lisinopril 
and enalapril, ranging from 30 to 245 Rubles, corrective therapy—from 284 to 583 
Rubles. In the economic evaluation of SE was the least expensive scheme with drug 
enalapril, which is more advantageous from an economic position. CONCLUSIONS: 
The economic analysis of side effects developing on the background of the basic course 
of pharmacotherapy, is relevant assessment to improve the quality and credibility of 
pharmacoeconomics studies of drugs.
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OBJECTIVES: Magnetic resonance imaging (MRI) is considered the gold standard for 
imaging of the brain, spinal cord, musculoskeletal system, and complex cardiac 
malfor mations. However, pacemaker implant is a contraindication to MRI, and thus 
a barrier to access in pacemaker-implanted patients for this essential diagnostic tech-
nology. An analysis of Medicare fee-for-service data was conducted to estimate the 
difference in MRI uptake rates of pacemaker-implanted and non-implanted Medicare 
benﬁ ciaries. METHODS: The data comprised the fee-for-service portion of the 2008 
Medicare patient population. Two issues were examined: the prevalence of the diseases 
for which MRI is the preferred imaging modality, and the uptake rates of all imaging 
modalities for MRI-indicated beneﬁ ciaries with pacemaker implants compared with 
those having no implants. For each of diseases for which MRI is the preferred modality 
we also identiﬁ ed any trade-offs between lower MRI rates and higher rates for other 
imaging modalities in pacemaker-implanted and non-implanted patients, and potential 
cost implications substituting MRI with other imaging modalities. RESULTS: The 
Medicare data indicated MRI uptake was nil in the pacemaker-implanted population 
where 13% of patients without any implant received MRI in 2008 suggesting that 
clinical practice is in line with the contraindication for MRI in pacemaker patients. 
Consequently, uptake of other imaging approaches including CT, ultrasound, nuclear, 
x-ray was greater in the MRI-indicated cohort of pacemaker patients (54%, 65%, 
25%, 82%, respectively) compared to the similar non-implanted cohort (38%, 48%, 
18%, 73%, respectively). It was estimated that access to MRI (i.e. patients implanted 
with MRI-compatible pacemakers) would generate up to 21% reduced diagnostic 
costs compared with no access to MRI (i.e. patients implanted with older generation 
pacemakers). CONCLUSIONS: Increased access to the diagnostic superiority of MRI 
may provide a more efﬁ cient allocation of diagnostic resources for pacemaker patients; 
this increased access can be provided with the availability in the market of new pace-
makers engineered for MRI compatibility.
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OBJECTIVES: As part of a broader HTA project on ablation procedures for atrial 
ﬁ brillation (A-AF), objective of this study was to quantify consumption of resources 
and calculate cost of A-AF in comparison with current reimbursement in Italy. 
METHODS: A questionnaire was sent to the Italian electrophysiology (EP) centres 
identiﬁ ed by AIAC (Italian Society of Cardiac Pacing and Arrhythmology) to collect, 
2008 data on: number of procedures; use of pre-post ablation diagnostics, consum-
ables, electro-anatomic mapping, anaesthesia/analgesia, EP laboratory occupancy 
time, staff employed; EP laboratory equipment; duration of hospitalization. Bottom-
up costing of resources was performed based on average costs from a sub-sample of 
4 hospitals, national tariffs or published data. Average procedure cost was calculated 
based on mathematical (m-mat) and geometrical (m-geo) means. Final endpoint was 
the comparison between DRG-518 regional reimbursement values and full hospital 
costs for ablation treatment. RESULTS: A total of 52/87 (60%) AIAC centres replied 
to the questionnaire, reporting 33,745 EP procedures, of which 4,561 (13.52%) were 
A-AF (min = 3; max = 1091; average = 88; SD = 159, median = 49; IQR = 22–81). 
Production cost for A-AF amounted to c9455 (m-mat) and c8868 (m-geo): consum-
ables (ablation and diagnostic catheters, transeptal needles, transeptal sheaths, and 
other devices) accounted for 61% of total cost; hospital stay 15%; intra-procedural 
costs (room occupancy, staff, anaesthesia and equipment) 20%; pre-procedural tests 
4%. Difference of DRG-518 tariff vs. hospital incurred costs: m-mat c−4079 (−43%) 
or m-geo c−3492 (−35%). Cost of production appears more under-remunerated in 
Lazio (−54%), Lombardia (−46%), Veneto, Umbria (−45%). The imbalance was 
